Tarsus Pharmaceuticals (TARS) Total Liabilities (2019 - 2026)
Tarsus Pharmaceuticals (TARS) posted quarterly Total Liabilities of $232.2 million for Q1 2026, up 46.68% year-over-year from $158.3 million in Q1 2025, and up 6.15% quarter-over-quarter from $218.7 million in Q4 2025.
Tarsus Pharmaceuticals (TARS) Total Liabilities (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Total Liabilities history runs 8 years deep, the most recent figure standing at $232.2 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 46.68% year-over-year to $232.2 million; the TTM figure through Mar 2026 stood at $232.2 million (up 46.68% YoY), while the FY2025 annual figure was $218.7 million, up 43.47% from the prior year.
- Total Liabilities for Q1 2026 stood at $232.2 million, up from $218.7 million in the prior quarter.
- The five-year high for Total Liabilities was $232.2 million in Q1 2026, with the low at $31.3 million in Q2 2022.
- The 5-year median for Total Liabilities is $74.1 million (2024), against an average of $105.6 million.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities gained 17.11% in 2023, then jumped 202.44% in 2024.
- Tarsus Pharmaceuticals' Total Liabilities stood at $35.0 million in 2022, then surged by 95.93% to $68.5 million in 2023, then jumped by 122.56% to $152.5 million in 2024, then surged by 43.47% to $218.7 million in 2025, then gained by 6.15% to $232.2 million in 2026.
- Business Quant data shows TARS's Total Liabilities at $232.2 million in Q1 2026, $218.7 million in Q4 2025, and $199.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Tarsus Pharmaceuticals | 2.99 Bn | 2.54 Bn | 161.80 Mn | 264.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 264.41 Mn |
| Mar 31, 2026 | 232.18 Mn |
| Dec 31, 2025 | 218.73 Mn |
| Sep 30, 2025 | 199.48 Mn |
| Jun 30, 2025 | 162.38 Mn |
| Mar 31, 2025 | 158.29 Mn |
| Dec 31, 2024 | 152.46 Mn |
| Sep 30, 2024 | 138.82 Mn |
| Jun 30, 2024 | 124.60 Mn |
| Mar 31, 2024 | 74.07 Mn |
| Dec 31, 2023 | 68.50 Mn |
| Sep 30, 2023 | 54.67 Mn |
| Jun 30, 2023 | 41.20 Mn |
| Mar 31, 2023 | 37.81 Mn |
| Dec 31, 2022 | 34.96 Mn |
| Sep 30, 2022 | 33.84 Mn |
| Jun 30, 2022 | 31.32 Mn |
| Mar 31, 2022 | 32.29 Mn |
| Dec 31, 2021 | 12.18 Mn |
| Sep 30, 2021 | 11.27 Mn |